$MAIA

Guerrero Ramiro purchased $2K of MAIA

Guerrero Ramiro purchased 1,794 shares of MAIA Biotechnology, Inc. (MAIA) at $1.33 on 2026-08-24.

Original reporting
SEC EDGAR · Guerrero Ramiro
Published Aug 26, 2026, 11:56 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 26, 2026, 12:09 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$MAIA
Neutral
high confidence
Mentioned
$MAIA
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MAIANeutralLow
01

Why it matters

The transaction is modest and unlikely to move the stock significantly, but it adds to the insider buying record.

02

Market read

Limited relevance; primarily of interest to investors tracking insider activity.

03

What to watch

Potential upcoming clinical trial data or partnership not disclosed yet.

Relevance 4/10Novelty 3/10Timing: filed today

Background

Form 4 filings disclose insider trades; this filing reports a director's purchase of MAIA shares.

Company-level read

Ticker impact

$MAIANeutralHigh confidence
Context

Director Guerrero Ramiro bought 1,794 shares of MAIA at $1.33, increasing his stake to 601,911 shares.

Expected impact

Minimal short-term price movement expected.

Evidence & confidence

The purchase is under $5k and represents a routine insider transaction; markets typically view such small buys as low significance.

Market effects

Negligible effect on biotech sector; no broader industry signal.

None

None

Counterpoint

Even small insider buys can precede larger moves if management anticipates upcoming catalyst.

Key entities

  • MAIA Biotechnology, Inc.

    US-listed biotech company (ticker MAIA).

  • Guerrero Ramiro

    Director of MAIA who purchased shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$UPCMed

6 After-Hours Healthcare Gainers: Universe Pharma, BioAffinity, Modular Medical, Telix Pharma & More

Universe Pharmaceuticals (UPC) rose 34.89% after-hours due to multiple Schedule 13G filings. BioAffinity (BIAF) explores new uses for its CyPath Lung test, up 3%. Modular Medical (MODD) gained 7% after announcing a product launch. MAIA (MAIA) rose 6% following an insider purchase. Telix (TLX) completed a Phase 3 study, up 2.21%. aTyr Pharma (ATYR) awaits FDA response, up 4%.

$MAIAMedAI 8/10

MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial

MAIA Biotechnology (NYSE American: MAIA) reported initial Phase 2 THIO-101 Part C data in third-line advanced NSCLC. Ateganosine followed by cemiplimab (Libtayo) produced a 90.5% disease control rate (19/21) in 3L patients, compared with 25-35% for standard chemotherapy. MAIA said safety is acceptable and enrollment is completed internationally.